Avita Medical Ltd (RCEL)

[MONYMAN3]

Some highlights:
Summary
Avita has a modest existing business selling its skin regeneration products.
Its shares have dropped recently despite several successes with the FDA.
Avita's near term catalysts offer sterling prospects for recovery to former highs and beyond.
While Avita has a nice potential upside it also has significant risks.
When sales and marketing expenses go up while gross profits are declining, as they did on a nine month basis, it sends a rude message

Despite its share price drops, the FDA has generally responded favorably to Avita's RECELL device

Avita's planned FDA applications for soft tissue repair and vitiligo are important near term catalysts.

Soft tissue reimbursement is already set. For vitiligo Avita targets it to take until 01/2025 to work out an acceptable reimbursement program.